Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Lee

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Oncogene|July 30, 2020
Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencingYuchen Wang, Yanna Liu, Wenfeng Deng, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 27, 2009
NCCN task force: clinical utility of PET in a variety of tumor typesDonald A Podoloff, Douglas W Ball, Edgar Ben-Josef, et al.
Oncotarget|October 10, 2014
The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cellsLymor Ringer, Paul Sirajuddin, Lucas Tricoli, et al.
JAMA Oncology|September 1, 2022
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical TrialNizar M Tannir, Neeraj Agarwal, Camillo Porta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
Science (New York, N.Y.)|September 19, 2015
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistanceDavid T Miyamoto, Yu Zheng, Ben S Wittner, et al.
Science Translational Medicine|April 29, 2010
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancerShannon L Stott, Richard J Lee, Sunitha Nagrath, et al.
Cell|June 16, 2023
DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCsHongshan Guo, Joanna A Vuille, Ben S Wittner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2023
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder CancerSophia C Kamran, Yuzhen Zhou, Keisuke Otani, et al.
Nature Communications|February 10, 2017
Expression of β-globin by cancer cells promotes cell survival during blood-borne disseminationYu Zheng, David T Miyamoto, Ben S Wittner, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Oncogene|July 30, 2020
Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencingYuchen Wang, Yanna Liu, Wenfeng Deng, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 27, 2009
NCCN task force: clinical utility of PET in a variety of tumor typesDonald A Podoloff, Douglas W Ball, Edgar Ben-Josef, et al.
Oncotarget|October 10, 2014
The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cellsLymor Ringer, Paul Sirajuddin, Lucas Tricoli, et al.
JAMA Oncology|September 1, 2022
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical TrialNizar M Tannir, Neeraj Agarwal, Camillo Porta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
Science (New York, N.Y.)|September 19, 2015
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistanceDavid T Miyamoto, Yu Zheng, Ben S Wittner, et al.
Science Translational Medicine|April 29, 2010
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancerShannon L Stott, Richard J Lee, Sunitha Nagrath, et al.
Cell|June 16, 2023
DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCsHongshan Guo, Joanna A Vuille, Ben S Wittner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2023
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder CancerSophia C Kamran, Yuzhen Zhou, Keisuke Otani, et al.
Nature Communications|February 10, 2017
Expression of β-globin by cancer cells promotes cell survival during blood-borne disseminationYu Zheng, David T Miyamoto, Ben S Wittner, et al.
Pageof 10